Table 2. Rucaparib-related (possibly, probably or almost certainly) adverse events (AEs) that occurred in at least 3 of all 78 patients by grade.

	Maximum CTCAE grade per patient for all dose levels, no. (%)
Adverse event	Grade 1	Grade 2	Grade 3
Nausea	22 (28)	4 (5)	2 (3)
Fatigue	20 (26)	15 (19)	5 (6)
Headache	12 (15)	5 (6)	0 (0)
Diarrhoea	11 (14)	1 (1)	0 (0)
Infusion site reactiona	5 (11)	1 (2)	0 (0)
Dizziness	8 (10)	1 (1)	0 (0)
Vomiting	7 (9)	3 (4)	0 (0)
Anorexia	7 (9)	1 (1)	0 (0)
Constipation	6 (8)	1 (1)	0 (0)
Alopecia	6 (8)	0 (0)	0 (0)
Pruritus	4 (5)	1 (1)	0 (0)
Taste alteration (dysgeusia)	4 (5)	1 (1)	0 (0)
Anaemia	0 (0)	4 (5)	0 (0)
Neutropenia	3 (4)	1 (1)	0 (0)
Dry mouth (xerostomia)	3 (4)	0 (0)	0 (0)
Elevated transaminase (AST)	3 (4)	0 (0)	0 (0)
Low mood	3 (4)	0 (0)	1 (1)
Sensory neuropathy	3 (4)	0 (0)	0 (0)
Abdominal pain	2 (3)	2 (3)	1 (1)
Arthralgia	3 (4)	2 (3)	0 (0)
Myalgia	2 (3)	1 (1)	0 (0)
Lymphopenia	1 (1)	2 (3)	0 (0)

Abbreviations: AST=aspartate transaminase; CTCAE=Common Terminology Criteria for Adverse Events.

Data are patient number (%). There were no grade 4/5 AEs.

^aIntravenous (i.v.) cohort only (n=47).